Abstract:BACKGROUND:Clinically, behavior, cognitive, and mental functions are affected during the neurodegenerative disease progression. To date, the molecular pathogenesis of these complex disease is still unclear. With the rapid development of sequencing technologies, it is possible to delicately decode the molecular mechanisms corresponding to different clinical phenotypes at the genome-wide transcriptomic level using computational methods. Our previous studies have shown that it is difficult to distinguish disease genes from non-disease genes. Therefore, to precisely explore the molecular pathogenesis under complex clinical phenotypes, it is better to identify biomarkers corresponding to different disease stages or clinical phenotypes. So, in this study, we designed a label propagation-based semi-supervised feature selection approach (LPFS) to prioritize disease-associated genes corresponding to different disease stages or clinical phenotypes. METHODS:In this study, we pioneering put label propagation clustering and feature selection into one framework and proposed label propagation-based semi-supervised feature selection approach. LPFS prioritizes disease genes related to different disease stages or phenotypes through the alternative iteration of label propagation clustering based on sample network and feature selection with gene expression profiles. Then the GO and KEGG pathway enrichment analysis were carried as well as the gene functional analysis to explore molecular mechanisms of specific disease phenotypes, thus to decode the changes in individual behavioral and mental characteristics during neurodegenerative disease progression. RESULTS:Large amounts of experiments were conducted to verify the performance of LPFS with Huntington's gene expression data. Experimental results shown that LPFS performs better in comparison with the-state-of-art methods. GO and KEGG enrichment analysis of key gene sets shown that TGF-beta signaling pathway, cytokine-cytokine receptor interaction, immune response, and inflammatory response were gradually affected during the Huntington's disease progression. In addition, we found that the expression of SLC4A11, ZFP474, AMBP, TOP2A, PBK, CCDC33, APSL, DLGAP5, and Al662270 changed seriously by the development of the disease. CONCLUSIONS:In this study, we designed a label propagation-based semi-supervised feature selection model to precisely selected key genes of different disease phenotypes. We conducted experiments using the model with Huntington's disease mice gene expression data to decode the mechanisms of it. We found many cell types, including astrocyte, microglia, and GABAergic neuron, could be involved in the pathological process.

K-means Based Unsupervised Feature Selection to Prioritize Biomarkers of Different Disease Clinical Phases

Multi-scale supervised clustering-based feature selection for tumor classification and identification of biomarkers and targets on genomic data

Ensemble Consensus-Guided Unsupervised Feature Selection To Identify Huntington'S Disease-Associated Genes

Label Propagation-Based Semi-Supervised Feature Selection on Decoding Clinical Phenotypes with RNA-seq Data

Prognostic enrichment for early-stage Huntington's disease: An explainable machine learning approach for clinical trial

Identification of key genes and signaling pathway in the pathogenesis of Huntington's disease via bioinformatics and next generation sequencing data analysis

Identifying disease‐associated biomarker network features through conditional graphical model

Identifying and verifying Huntington's disease subtypes: Clinical features, neuroimaging, and cytokine changes

Coupling bootstrap with synergy self-organizing map-based orthogonal partial least squares discriminant analysis: Stable metabolic biomarker selection for inherited metabolic diseases

The Use of Feature Selection Based Data Mining Methods in Biomarkers Identification of Disease

Hybrid Causal Feature Selection for Cancer Biomarker Identification from RNA-seq Data

The Unsupervised Feature Selection Algorithms Based on Standard Deviation and Cosine Similarity for Genomic Data Analysis

Automated Huntington's Disease Prognosis via Biomedical Signals and Shallow Machine Learning

Outcome-guided Sparse K-means for Disease Subtype Discovery via Integrating Phenotypic Data with High-dimensional Transcriptomic Data

Neuroimaging biomarkers in Huntington's disease: Preparing for a new era of therapeutic development

Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review

A three-stage approach to identify biomarker signatures for cancer genetic data with survival endpoints

Identifying Metabolite Biomarkers in Unstable Angina In-Patients by Feature Selection Based Data Mining Methods

An ensemble learning-based feature selection algorithm for identification of biomarkers of renal cell carcinoma

Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression

Multi-modal biological feature selection for Parkinson's disease staging based on binary PSO with broad learning